V-Square Quantitative Management’s Neurocrine Biosciences NBIX Stock Holding History

V-Square Quantitative Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,711	Closed	-$225K	–	765
2026 Q1	$225K	Buy	1,711 +35	+2%	+$4.64K	0.02%	508
2025 Q4	$238K	Buy	+1,676	New	+$243K	0.02%	503
2025 Q3	–	Sell	-1,550	Closed	-$195K	–	430
2025 Q2	$195K	Buy	1,550 +31	+2%	+$3.56K	0.03%	502
2025 Q1	$168K	Buy	1,519 +92	+6%	+$11.7K	0.02%	521
2024 Q4	$195K	Buy	1,427 +9	+0.6%	+$1.11K	0.03%	512
2024 Q3	$163K	Buy	1,418 +82	+6%	+$11.2K	0.02%	525
2024 Q2	$184K	Buy	+1,336	New	+$183K	0.03%	511
2023 Q3	–	Sell	-143	Closed	-$13.5K	–	555
2023 Q2	$13.5K	Buy	+143	New	+$14K	0.01%	404

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

V-Square Quantitative Management's NBIX Position: Q2 2026 in Review

V-Square Quantitative Management sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 1,711 shares — an estimated $225K sold.

V-Square Quantitative Management first reported a position in NBIX in Q2 2023 and held it in 8 quarters. The position peaked at $238K in Q4 2025. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

V-Square Quantitative Management reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
V-Square Quantitative Management sold 1,711 Neurocrine Biosciences shares in Q2 2026, an estimated $225K.
V-Square Quantitative Management first reported a position in Neurocrine Biosciences in Q2 2023 and held it in 8 quarters.
V-Square Quantitative Management's Neurocrine Biosciences position peaked at $238K in Q4 2025.
777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on V-Square Quantitative Management's 13F filing for Q2 2026, filed 27 Jul 2026.